Published January 31, 2024
| Version http://impactfactor.org/PDF/IJTPR/14/IJTPR,Vol14,Issue1,Article11.pdf
Journal article
Open
Navigating the Therapeutic Landscape: Unveiling the Efficiency and Safety of Oral Tofacitinib in Patients with Rheumatoid Arthritis
Authors/Creators
- 1. Associate Professor, Department of Orthopaedics Datta Meghe Medical College, Datta Meghe Institute of Higher Education and Research (DU), Sawangi (Meghe), Wardha, Maharashtra, India
- 2. Associate Professor, Department of Orthopaedics Datta Meghe Medical College, Datta Meghe Institute of Higher Education and Research (DU), Sawangi (Meghe), Wardha, Maharashtra, India.
- 3. Professor, Department of Orthopaedics Datta Meghe Medical College, Datta Meghe Institute of Higher Education and Research (DU), Sawangi (Meghe), Wardha, Maharashtra, India.
Description
Rheumatoid arthritis (RA) looms large as a formidable adversary within the intricate landscape of autoimmune disorders, casting its shadow over millions of individuals worldwide. The prevalence of rheumatoid arthritis transcends geographic boundaries, affecting diverse populations with varying genetic predispositions and environmental factors. Understanding the nuances of patient-specific factors that may influence treatment outcomes is crucial in tailoring therapeutic approaches. The results of this study highlight the efficacy of oral tofacitinib in reducing disease activity, improving functional status, and inhibiting joint damage progression in patients with rheumatoid arthritis.
Abstract (English)
Rheumatoid arthritis (RA) looms large as a formidable adversary within the intricate landscape of autoimmune disorders, casting its shadow over millions of individuals worldwide. The prevalence of rheumatoid arthritis transcends geographic boundaries, affecting diverse populations with varying genetic predispositions and environmental factors. Understanding the nuances of patient-specific factors that may influence treatment outcomes is crucial in tailoring therapeutic approaches. The results of this study highlight the efficacy of oral tofacitinib in reducing disease activity, improving functional status, and inhibiting joint damage progression in patients with rheumatoid arthritis.
Files
IJTPR,Vol14,Issue1,Article11.pdf
Files
(312.3 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:c4dd1fb316919f1cad7e2ebbc0e25e2a
|
312.3 kB | Preview Download |
Additional details
Dates
- Accepted
-
2023-12-15
Software
References
- 1. Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, Xu J. Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Res. 2018;6(1):15. 2. Jamilloux Y, El Jammal T, Vuitton L, GerfaudValentin M, Kerever S, Sève P. JAK inhibitors for the treatment of autoimmune and inflammatory diseases. Autoimmun Rev. 2019; 18(11):102390. 3. Deane KD, Demoruelle MK, Kelmenson LB, Kuhn KA, Norris JM, Holers VM. Genetic and environmental risk factors for rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2017; 31(1):3-18. 4. Stein DJ, Shoptaw SJ, Vigo DV, et al. Psychiatric diagnosis and treatment in the 21st century: paradigm shifts versus incremental integration. World Psychiatry. 2022;21(3):393- 414. 5. Hodge JA, Kawabata TT, Krishnaswami S, et al. The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 201 6;34(2):318-328. 6. Sonthalia S, Aggarwal P. Oral tofacitinib: Contemporary appraisal of its role in dermatology. Indian Dermatol Online J. 2019;10(5): 503. 7. Navarro-Compán V, Wei JC -Chung, Van Den Bosch F, et al. Effect of tofacitinib on pain, fatigue, health-related quality of life and work productivity in patients with active ankylosing spondylitis: results from a phase III, randomised, double-blind, placebo-controlled trial. RMD Open. 2022;8(2):e002253. 8. Ly K, Beck KM, Smith MP, Orbai AM, Liao W. Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives. Psoriasis Targets Ther. 2019; 9:97-107. 9. Rippe JM. Lifestyle Strategies for Risk Factor Reduction, Prevention, and Treatment of Cardiovascular Disease. Am J Lifestyle Med. 2019 ;13(2):204-212. 10. 10. Tesser J, Gül A, Olech E, et al. Efficacy and safety of tofacitinib in patients with rheumatoid arthritis by previous treatment: post hoc analysis of phase II/III trials. Arthritis Res Ther. 2023;25(1):214. 11. J. Kucharz E, Stajszczyk M, Kotulska-Kucharz A, et al. Tofacitinib in the treatment of patients with rheumatoid arthritis: position statement of experts of the Polish Society for Rheumatology. Rheumatology. 2018;56(4):2 03-211. 12. Smolen JS, Aletaha D, Gruben D, Zwillich SH, Krishnaswami S, Mebus C. Brief Report: Remission Rates with Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria. Arthritis Rheumatol. 2017;69(4):728-734. 13. Mueller, Hasler, Popp, et al. Effectiveness, Tolerability, and Safety of Tofacitinib in Rheumatoid Arthritis: A Retrospective Analysis of Real-World Data from the St. Gallen and Aarau Cohorts. J Clin Med. 2019;8(10):1548. 14. Maska L, Anderson J, Michaud K. Measures of functional status and quality of life in rheumatoid arthritis: Health Assessment Questionnaire Disability Index (HAQ), Modified Health Assessment Questionnaire (MHAQ), Multidimensional Health Assessment Questionnaire (MDHAQ), Health Assessment Questionnaire II (HAQ‐II), Improved Health Assessment Questionnaire (Improved HAQ), and Rheumatoid Arthritis Quality of Life (RAQoL). Arthritis Care Res. 2011;63(S11). 15. Angelini J, Talotta R, Roncato R, et al. JAKInhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future. Biomolecules. 2020;10(7): 1002. 16. Sciascia S, Radin M, Cecchi I, et al. Tailoring Tofacitinib Oral Therapy in Rheumatoid Arthritis: The TuTORApp—A Usability Study. Int J Environ Res Public Health. 2020;17(10): 3469. 17. Kraev K, Geneva-Popova MG, Hristov BK, et al. Examining the Safety Profile of Janus Kinase (JAK) Inhibitors in the Management of Immune-Mediated Diseases: A Comprehensive Review. Life. 2023;13(12):2244. 18. Metlay JP, Waterer GW, Long AC, et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019; 200(7):e45-e67. 19. LeBoff MS, Greenspan SL, Insogna KL, et al. The clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int. 2022; 33 (10):2049-2102. 20. Wollenhaupt J, Lee EB, Curtis JR, et al. Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study. Arthritis Res Ther. 2019 ;21(1):89. 21. Kent DM, Rothwell PM, Ioannidis JP, Altman DG, Hayward RA. Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal. Trials. 2010;11(1): 8 5. 22. Dahabreh IJ, Hayward R, Kent DM. Using group data to treat individuals: understanding heterogeneous treatment effects in the age of precision medicine and patient-centred evidence. Int J Epidemiol. Published online November 17, 2016: dyw125. 23. 23. Ricci L, Villegente J, Loyal D, Ayav C, Kivits J, Rat A. Tailored patient therapeutic educational interventions: A patient‐centred communication model. Health Expect. 2022; 25(1):276-289. 24. 24. Kang H. Appropriate design of research and statistical analyses: observational versus experimental studies. Korean J Anesthesiol. 2013; 65(2):105. 25. Deakin CT, De Stavola BL, Littlejohn G, et al. Comparative Effectiveness of Adalimumab vs Tofacitinib in Patients with Rheumatoid Arthritis in Australia. JAMA Netw Open. 2023; 6(6): e2320851. 26. Ogdie A, De Vlam K, McInnes IB, et al. Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. RMD Open. 2020;6(1): e001042. 27. Dhillon S. Tofacitinib: A Review in Rheumatoid Arthritis. Drugs. 2017;77(18):1987-2001.